{"id":4457,"date":"2026-01-28T21:00:44","date_gmt":"2026-01-29T02:00:44","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/"},"modified":"2026-11-04T04:29:38","modified_gmt":"2026-11-04T03:29:38","slug":"gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/","title":{"rendered":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 28 janvier 2026, 22h00 CET<\/strong> \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce que son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire, r\u00e9unie ce jour \u00e0 15h00, a approuv\u00e9 l\u2019ensemble des r\u00e9solutions soumises au vote des actionnaires, \u00e0 l\u2019exception de la 8\u1d49 r\u00e9solution relative \u00e0 une augmentation de capital r\u00e9serv\u00e9e aux salari\u00e9s dans le cadre d\u2019un plan d\u2019\u00e9pargne d\u2019entreprise, qui a \u00e9t\u00e9 rejet\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les actionnaires ont notamment approuv\u00e9 le renouvellement de l\u2019ensemble des d\u00e9l\u00e9gations financi\u00e8res, en remplacement de celles pr\u00e9c\u00e9demment utilis\u00e9es, permettant \u00e0 la Soci\u00e9t\u00e9 de disposer de la flexibilit\u00e9 financi\u00e8re n\u00e9cessaire \u00e0 la poursuite de sa strat\u00e9gie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019 Assembl\u00e9e a \u00e9t\u00e9 tenue par Jan Eryk Umiastowski, Directeur G\u00e9n\u00e9ral D\u00e9l\u00e9gu\u00e9 et Directeur Financier, qui a r\u00e9pondu \u00e0 une question \u00e9crite, dont la r\u00e9ponse est disponible sur le site internet de la Soci\u00e9t\u00e9, et a apport\u00e9 des \u00e9claircissements aux diff\u00e9rentes questions pos\u00e9es par les actionnaires au cours de la s\u00e9ance.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le rejet de la 8\u1d49 r\u00e9solution, sans impact sur les d\u00e9l\u00e9gations financi\u00e8res, n\u2019affecte pas la capacit\u00e9 de la Soci\u00e9t\u00e9 \u00e0 r\u00e9aliser des op\u00e9rations sur le capital.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le r\u00e9sultat du scrutin par r\u00e9solution et la retransmission de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale sont disponibles sur le site internet de la Soci\u00e9t\u00e9 dans la rubrique Investisseurs (<a href=\"https:\/\/www.gensight-biologics.com\/fr\/investisseurs-media\/\">www.gensight-biologics.com\/fr\/investisseurs-media\/<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 28 janvier 2026, 22h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce que son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire, r\u00e9unie ce jour \u00e0 [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[85],"news-type":[76,82],"post-year":[98],"class_list":["post-4457","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-general-meeting","news-type-corporate","news-type-general-meeting","post-year-98"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026 | GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026 | GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 28 janvier 2026, 22h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce que son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire, r\u00e9unie ce jour \u00e0 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T02:00:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-04T03:29:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Emmanuelle Lopez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emmanuelle Lopez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/01\\\/28\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/01\\\/28\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\\\/\"},\"author\":{\"name\":\"Emmanuelle Lopez\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/9faedbb40f86c915ee54c6a532358bbd\"},\"headline\":\"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026\",\"datePublished\":\"2026-01-29T02:00:44+00:00\",\"dateModified\":\"2026-11-04T03:29:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/01\\\/28\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\\\/\"},\"wordCount\":299,\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Communiqu\u00e9 de presse financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/01\\\/28\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/01\\\/28\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\\\/\",\"name\":\"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026 | GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-01-29T02:00:44+00:00\",\"dateModified\":\"2026-11-04T03:29:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/01\\\/28\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/01\\\/28\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/01\\\/28\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\",\"name\":\"GenSight Biologics\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"contentUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"width\":696,\"height\":696,\"caption\":\"GenSight Biologics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/8104807?trk=prof-exp-company-name\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/9faedbb40f86c915ee54c6a532358bbd\",\"name\":\"Emmanuelle Lopez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g\",\"caption\":\"Emmanuelle Lopez\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026 | GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026 | GenSight Biologics","og_description":"Paris, France, le 28 janvier 2026, 22h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce que son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire, r\u00e9unie ce jour \u00e0 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/","og_site_name":"GenSight Biologics","article_published_time":"2026-01-29T02:00:44+00:00","article_modified_time":"2026-11-04T03:29:38+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-1.jpg","type":"image\/jpeg"}],"author":"Emmanuelle Lopez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Emmanuelle Lopez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/"},"author":{"name":"Emmanuelle Lopez","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/9faedbb40f86c915ee54c6a532358bbd"},"headline":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026","datePublished":"2026-01-29T02:00:44+00:00","dateModified":"2026-11-04T03:29:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/"},"wordCount":299,"publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"articleSection":["Communiqu\u00e9 de presse financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/","name":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026 | GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2026-01-29T02:00:44+00:00","dateModified":"2026-11-04T03:29:38+00:00","breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/01\/28\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-extraordinaire-du-28-janvier-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Extraordinaire du 28 janvier 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization","name":"GenSight Biologics","url":"https:\/\/www.gensight-biologics.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","contentUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","width":696,"height":696,"caption":"GenSight Biologics"},"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/8104807?trk=prof-exp-company-name"]},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/9faedbb40f86c915ee54c6a532358bbd","name":"Emmanuelle Lopez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0be6277f45fa8444499570eba9400a6880ce1445b6b08c41d46697b641e907c3?s=96&d=mm&r=g","caption":"Emmanuelle Lopez"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4457"}],"version-history":[{"count":1,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4457\/revisions"}],"predecessor-version":[{"id":10192,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4457\/revisions\/10192"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4457"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4457"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4457"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4457"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}